Last 12 months
Inside the activity.
33 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 32 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2023 Filed May 8, 2023 11:03 UTC |
Nabel Gary J.Director · Chief Innovation Officer
|
PurchaseCommon Stock | 26,407 | $1.85 | $48,852.95 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 9 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 19,912,459 F1 · ownership.nature: Shares held by the GJN 2021 TRUST for the benefit of the Reporting Person's spouse and descendants, and for which the Reporting Person's spouse serves as co-trustee together with an independent trustee. The Reporting Person's spouse and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC |
Nabel Gary J.Director · Chief Innovation Officer
|
PurchaseCommon Stock | 28,538 | $1.82 | $51,939.16 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 8 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 19,886,052 F1 · ownership.nature: Shares held by the GJN 2021 TRUST for the benefit of the Reporting Person's spouse and descendants, and for which the Reporting Person's spouse serves as co-trustee together with an independent trustee. The Reporting Person's spouse and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC |
Nabel Gary J.Director · Chief Innovation Officer
|
PurchaseCommon Stock | 10,928 | $1.83 | $19,998.24 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 7 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,079 Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC |
Nabel Gary J.Director · Chief Innovation Officer
|
PurchaseCommon Stock | 19,475 | $1.83 | $35,619.78 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 6 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,151 Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC |
Nabel Gary J.Director · Chief Innovation Officer
|
PurchaseCommon Stock | 79,334 | $1.82 | $144,387.88 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 5 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,676 Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC |
Nabel Gary J.Director · Chief Innovation Officer
|
PurchaseCommon Stock | 27,624 | $1.81 | $49,999.44 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 4 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,342 Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC |
Nabel Gary J.Director · Chief Innovation Officer
|
PurchaseCommon Stock | 27,777 | $1.80 | $49,998.60 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 3 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,718 Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC |
Nabel Gary J.Director · Chief Innovation Officer
|
PurchaseCommon Stock | 3,185 | $1.79 | $5,710.71 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 2 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,941 Read SEC document |
| May 05, 2023 Filed May 8, 2023 11:03 UTC |
Nabel Gary J.Director · Chief Innovation Officer
|
PurchaseCommon Stock | 19,285 | $1.78 | $34,327.30 |
DisclosureSEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,756 Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 10:52 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 352 | $1.33 | $468.16 |
DisclosureSEC source: 0001209191-23-020688 · doc4.xml · nonDerivative · entry 6 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 200,031,694 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 10:52 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 116,648 | $1.33 | $154,558.60 |
DisclosureSEC source: 0001209191-23-020688 · doc4.xml · nonDerivative · entry 5 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 200,031,342 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 10:52 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 25,200 | $1.32 | $33,264.00 |
DisclosureSEC source: 0001209191-23-020688 · doc4.xml · nonDerivative · entry 4 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 199,914,694 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 10:52 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 57,100 | $1.32 | $75,086.50 |
DisclosureSEC source: 0001209191-23-020688 · doc4.xml · nonDerivative · entry 3 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 199,889,494 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 10:52 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 700 | $1.31 | $917.00 |
DisclosureSEC source: 0001209191-23-020688 · doc4.xml · nonDerivative · entry 2 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 199,832,394 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 20,000 | $1.29 | $25,800.00 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 25 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,831,694 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 6,037 | $1.28 | $7,727.36 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 24 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,811,694 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 34,812 | $1.27 | $44,211.24 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 23 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,805,657 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 7,341 | $1.27 | $9,286.37 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 22 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,770,845 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 2,700 | $1.26 | $3,402.00 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 21 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,763,504 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 89,710 | $1.26 | $112,586.05 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 20 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,760,804 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 92,000 | $1.25 | $115,000.00 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 19 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,671,094 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 11,300 | $1.25 | $14,068.50 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 18 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,579,094 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 11,556 | $1.24 | $14,329.44 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 17 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,567,794 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 1,200 | $1.24 | $1,482.00 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 16 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,556,238 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 15,386 | $1.23 | $18,924.78 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 15 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,555,038 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 7,958 | $1.23 | $9,748.55 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 14 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,539,652 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 20,700 | $1.16 | $24,012.00 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 13 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,531,694 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 59,117 | $1.16 | $68,280.14 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 12 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,510,994 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 1,000 | $1.15 | $1,152.50 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 11 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,451,877 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 81,336 | $1.15 | $93,536.40 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 10 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,450,877 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 1,900 | $1.15 | $2,180.25 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 9 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,369,541 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 13,569 | $1.15 | $15,536.51 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 8 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,367,641 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 348,101 | $1.14 | $396,835.14 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 7 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,354,072 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 107,200 | $1.14 | $121,672.00 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 6 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 199,005,971 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 5,700 | $1.13 | $6,455.25 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 5 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 198,898,771 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 22,049 | $1.13 | $24,915.37 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 4 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 198,893,071 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 39,028 | $1.13 | $43,906.50 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 3 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 198,871,022 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 08, 2023 Filed Mar 9, 2023 11:26 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 300 | $1.12 | $336.00 |
DisclosureSEC source: 0001209191-23-017444 · doc4.xml · nonDerivative · entry 2 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 198,831,994 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 23:07 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
Grant5% Convertible Promissory Notes due 2025 · Derivative | Not disclosed | $25,000,000.00 Strike: $1.66 | $25,000,000.00 |
DisclosureSEC source: 0001209191-23-009339 · doc4.xml · derivative · entry 2 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 25,000,000 Underlying: Common Stock · Not disclosed shares Expires 2025-01-31 F1 · kind: The two reported transactions involved an amendment and restatement of an outstanding convertible promissory note (the "Original Note"), resulting in the deemed cancellation of the Original Note and the execution of an amended note (the "Amended Note"). The Original Note was entered into on February 27, 2018 and the Reporting Person had the option to convert all or any portion of the outstanding principal balance of the Original Note, plus unpaid interest, into shares of the Issuer's common stock, par value $0.01 per share, at a conversion price of $5.00 per share, at any time prior to the maturity date, which was February 27, 2023. The Amended Note extends the maturity to January 31, 2025, and resets the conversion price to the 10 day volume weighted average price immediately preceding the date of the Amended Note, plus a 25% conversion premium, or $1.66. F1 · derivative.exercise_date: The two reported transactions involved an amendment and restatement of an outstanding convertible promissory note (the "Original Note"), resulting in the deemed cancellation of the Original Note and the execution of an amended note (the "Amended Note"). The Original Note was entered into on February 27, 2018 and the Reporting Person had the option to convert all or any portion of the outstanding principal balance of the Original Note, plus unpaid interest, into shares of the Issuer's common stock, par value $0.01 per share, at a conversion price of $5.00 per share, at any time prior to the maturity date, which was February 27, 2023. The Amended Note extends the maturity to January 31, 2025, and resets the conversion price to the 10 day volume weighted average price immediately preceding the date of the Amended Note, plus a 25% conversion premium, or $1.66. F2 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 23:07 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
Disposition to issuer5% Convertible Promissory Notes due 2023 · Derivative | Not disclosed | $25,000,000.00 Strike: $5.00 | $25,000,000.00 |
DisclosureSEC source: 0001209191-23-009339 · doc4.xml · derivative · entry 1 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnore Disclosed balance after: 0 Underlying: Common Stock · Not disclosed shares Expires 2023-02-27 F1 · kind: The two reported transactions involved an amendment and restatement of an outstanding convertible promissory note (the "Original Note"), resulting in the deemed cancellation of the Original Note and the execution of an amended note (the "Amended Note"). The Original Note was entered into on February 27, 2018 and the Reporting Person had the option to convert all or any portion of the outstanding principal balance of the Original Note, plus unpaid interest, into shares of the Issuer's common stock, par value $0.01 per share, at a conversion price of $5.00 per share, at any time prior to the maturity date, which was February 27, 2023. The Amended Note extends the maturity to January 31, 2025, and resets the conversion price to the 10 day volume weighted average price immediately preceding the date of the Amended Note, plus a 25% conversion premium, or $1.66. F1 · derivative.exercise_date: The two reported transactions involved an amendment and restatement of an outstanding convertible promissory note (the "Original Note"), resulting in the deemed cancellation of the Original Note and the execution of an amended note (the "Amended Note"). The Original Note was entered into on February 27, 2018 and the Reporting Person had the option to convert all or any portion of the outstanding principal balance of the Original Note, plus unpaid interest, into shares of the Issuer's common stock, par value $0.01 per share, at a conversion price of $5.00 per share, at any time prior to the maturity date, which was February 27, 2023. The Amended Note extends the maturity to January 31, 2025, and resets the conversion price to the 10 day volume weighted average price immediately preceding the date of the Amended Note, plus a 25% conversion premium, or $1.66. F2 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 23:06 UTC |
HSIAO JANE PH DDirector · Vice Chairman & CTO
|
Grant5% Convertible Promissory Notes due 2025 · Derivative | Not disclosed | $5,000,000.00 Strike: $1.66 | $5,000,000.00 |
DisclosureSEC source: 0001209191-23-009337 · doc4.xml · derivative · entry 2 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2025-01-31 F1 · kind: The two reported transactions involved an amendment and restatement of an outstanding convertible promissory note (the "Original Note"), resulting in the deemed cancellation of the Original Note and the execution of an amended note (the "Amended Note"). The Original Note was entered into on February 27, 2018 and the Reporting Person had the option to convert all or any portion of the outstanding principal balance of the Original Note, plus unpaid interest, into shares of the Issuer's common stock, par value $0.01 per share, at a conversion price of $5.00 per share, at any time prior to the maturity date, which was February 27, 2023. The Amended Note extends the maturity to January 31, 2025, and resets the conversion price to the 10 day volume weighted average price immediately preceding the date of the Amended Note, plus a 25% conversion premium, or $1.66. F1 · derivative.exercise_date: The two reported transactions involved an amendment and restatement of an outstanding convertible promissory note (the "Original Note"), resulting in the deemed cancellation of the Original Note and the execution of an amended note (the "Amended Note"). The Original Note was entered into on February 27, 2018 and the Reporting Person had the option to convert all or any portion of the outstanding principal balance of the Original Note, plus unpaid interest, into shares of the Issuer's common stock, par value $0.01 per share, at a conversion price of $5.00 per share, at any time prior to the maturity date, which was February 27, 2023. The Amended Note extends the maturity to January 31, 2025, and resets the conversion price to the 10 day volume weighted average price immediately preceding the date of the Amended Note, plus a 25% conversion premium, or $1.66. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 23:06 UTC |
HSIAO JANE PH DDirector · Vice Chairman & CTO
|
Disposition to issuer5% Convertible Promissory Notes due 2023 · Derivative | Not disclosed | $5,000,000.00 Strike: $5.00 | $5,000,000.00 |
DisclosureSEC source: 0001209191-23-009337 · doc4.xml · derivative · entry 1 HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2023-02-27 F1 · kind: The two reported transactions involved an amendment and restatement of an outstanding convertible promissory note (the "Original Note"), resulting in the deemed cancellation of the Original Note and the execution of an amended note (the "Amended Note"). The Original Note was entered into on February 27, 2018 and the Reporting Person had the option to convert all or any portion of the outstanding principal balance of the Original Note, plus unpaid interest, into shares of the Issuer's common stock, par value $0.01 per share, at a conversion price of $5.00 per share, at any time prior to the maturity date, which was February 27, 2023. The Amended Note extends the maturity to January 31, 2025, and resets the conversion price to the 10 day volume weighted average price immediately preceding the date of the Amended Note, plus a 25% conversion premium, or $1.66. F1 · derivative.exercise_date: The two reported transactions involved an amendment and restatement of an outstanding convertible promissory note (the "Original Note"), resulting in the deemed cancellation of the Original Note and the execution of an amended note (the "Amended Note"). The Original Note was entered into on February 27, 2018 and the Reporting Person had the option to convert all or any portion of the outstanding principal balance of the Original Note, plus unpaid interest, into shares of the Issuer's common stock, par value $0.01 per share, at a conversion price of $5.00 per share, at any time prior to the maturity date, which was February 27, 2023. The Amended Note extends the maturity to January 31, 2025, and resets the conversion price to the 10 day volume weighted average price immediately preceding the date of the Amended Note, plus a 25% conversion premium, or $1.66. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 12:10 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 19,655 | $1.51 | $29,679.05 |
DisclosureSEC source: 0001209191-22-058551 · doc4.xml · nonDerivative · entry 9 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 198,831,694 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 12:10 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 6,345 | $1.51 | $9,549.23 |
DisclosureSEC source: 0001209191-22-058551 · doc4.xml · nonDerivative · entry 8 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 198,812,039 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 12:10 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 75,496 | $1.50 | $113,244.00 |
DisclosureSEC source: 0001209191-22-058551 · doc4.xml · nonDerivative · entry 7 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 198,805,694 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 12:10 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 11,551 | $1.49 | $17,210.99 |
DisclosureSEC source: 0001209191-22-058551 · doc4.xml · nonDerivative · entry 6 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 198,730,198 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 12:10 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 93,500 | $1.49 | $138,847.50 |
DisclosureSEC source: 0001209191-22-058551 · doc4.xml · nonDerivative · entry 5 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 198,718,647 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 12:10 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 1,200 | $1.48 | $1,779.00 |
DisclosureSEC source: 0001209191-22-058551 · doc4.xml · nonDerivative · entry 4 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 198,625,147 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 12:10 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 58,006 | $1.48 | $85,848.88 |
DisclosureSEC source: 0001209191-22-058551 · doc4.xml · nonDerivative · entry 3 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 198,623,947 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 12:10 UTC |
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
Frost Gamma Investments Trust10% owner
|
PurchaseCommon Stock | 34,247 | $1.48 | $50,514.33 |
DisclosureSEC source: 0001209191-22-058551 · doc4.xml · nonDerivative · entry 2 FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner Frost Gamma Investments Trust · CIK 0001380896 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 198,565,941 F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.